CMO PCL (BKK:CMO)
Thailand · Delayed Price · Currency is THB 0.5400
+0.0100 (1.89%)
Aug 6, 2025, 4:23 PM ICT
Verve Therapeutics Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 1,420 | 1,248 | 1,279 | 1,189 | 483.99 | 717.95 | Upgrade |
Other Revenue | 9.2 | 8.95 | 10.43 | - | - | - | Upgrade |
| 1,429 | 1,257 | 1,289 | 1,189 | 483.99 | 717.95 | Upgrade | |
Revenue Growth (YoY) | 15.48% | -2.53% | 8.45% | 145.61% | -32.59% | -46.34% | Upgrade |
Cost of Revenue | 1,051 | 975.18 | 1,069 | 970.91 | 459.72 | 694.75 | Upgrade |
Gross Profit | 378.79 | 281.36 | 220.34 | 217.79 | 24.26 | 23.2 | Upgrade |
Selling, General & Admin | 289.56 | 303.66 | 338.24 | 227.96 | 140.35 | 191.64 | Upgrade |
Other Operating Expenses | - | - | - | -6.25 | -11.41 | - | Upgrade |
Operating Expenses | 289.56 | 303.66 | 338.24 | 221.71 | 128.94 | 202.55 | Upgrade |
Operating Income | 89.23 | -22.3 | -117.9 | -3.92 | -104.67 | -179.35 | Upgrade |
Interest Expense | -19.15 | -20.51 | -27 | -20.11 | -21.18 | -20.97 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | - | 9.29 | Upgrade |
EBT Excluding Unusual Items | 70.08 | -42.81 | -144.89 | -24.03 | -125.86 | -191.03 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 20.22 | Upgrade |
Pretax Income | 70.08 | -42.81 | -144.89 | -24.03 | -125.86 | -170.81 | Upgrade |
Income Tax Expense | 54.08 | 42.39 | 11.63 | 2.57 | -8.49 | -37.65 | Upgrade |
Earnings From Continuing Operations | 16 | -85.2 | -156.53 | -26.59 | -117.37 | -133.15 | Upgrade |
Minority Interest in Earnings | -25.95 | -12.74 | -12.69 | -4.8 | -3.14 | 3.17 | Upgrade |
Net Income | -9.96 | -97.95 | -169.22 | -31.39 | -120.51 | -129.98 | Upgrade |
Net Income to Common | -9.96 | -97.95 | -169.22 | -31.39 | -120.51 | -129.98 | Upgrade |
Shares Outstanding (Basic) | 473 | 417 | 281 | 270 | 255 | 255 | Upgrade |
Shares Outstanding (Diluted) | 473 | 417 | 281 | 270 | 255 | 255 | Upgrade |
Shares Change (YoY) | 68.21% | 48.58% | 3.93% | 5.83% | - | - | Upgrade |
EPS (Basic) | -0.02 | -0.23 | -0.60 | -0.12 | -0.47 | -0.51 | Upgrade |
EPS (Diluted) | -0.02 | -0.23 | -0.60 | -0.12 | -0.47 | -0.51 | Upgrade |
Free Cash Flow | 178.62 | 142.73 | -54.6 | -82.74 | 10.49 | -31.06 | Upgrade |
Free Cash Flow Per Share | 0.38 | 0.34 | -0.19 | -0.31 | 0.04 | -0.12 | Upgrade |
Gross Margin | 26.50% | 22.39% | 17.09% | 18.32% | 5.01% | 3.23% | Upgrade |
Operating Margin | 6.24% | -1.77% | -9.14% | -0.33% | -21.63% | -24.98% | Upgrade |
Profit Margin | -0.70% | -7.80% | -13.13% | -2.64% | -24.90% | -18.11% | Upgrade |
Free Cash Flow Margin | 12.50% | 11.36% | -4.23% | -6.96% | 2.17% | -4.33% | Upgrade |
EBITDA | 134.68 | 24.71 | -85.25 | 35.51 | -65.04 | -82.66 | Upgrade |
EBITDA Margin | 9.42% | 1.97% | -6.61% | 2.99% | -13.44% | -11.51% | Upgrade |
D&A For EBITDA | 45.45 | 47.01 | 32.65 | 39.43 | 39.63 | 96.69 | Upgrade |
EBIT | 89.23 | -22.3 | -117.9 | -3.92 | -104.67 | -179.35 | Upgrade |
EBIT Margin | 6.24% | -1.77% | -9.14% | -0.33% | -21.63% | -24.98% | Upgrade |
Effective Tax Rate | 77.18% | - | - | - | - | - | Upgrade |
Revenue as Reported | 1,429 | 1,257 | 1,289 | - | - | - | Upgrade |
Advertising Expenses | - | 4.88 | 2.15 | 4 | 2 | - | Upgrade |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.